Reimbursed Care Access in Zimbabwe

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Zimbabwe Dangerous Drugs Act’s schedule explicitly lists psilocybin/psilocine (and related tryptamines) among prohibited substances, meaning import, possession, manufacture or sale is subject to criminal penalties except where a Ministerial licence for research or other limited purpose is issued under the Act. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Dangerous Drugs Act schedule explicitly lists MDMA/MDM/“Ecstasy” as a prohibited psychotropic substance; therefore commercial or clinical therapeutic use is not permitted except in formally licensed trials or with explicit Ministerial/regulatory authorisation. #

Esketamine (Spravato or other esketamine products) is not shown in Zimbabwe’s public medicines/registration listings and there is no evidence of an approved national rollout or reimbursement pathway through the Medicines Control Authority of Zimbabwe (MCAZ). The MCAZ maintains a register of approved/registered medicines and procedures for registration and variations; no listed public documentation indicates Spravato/esketamine registration or a national REMS‑style programme in Zimbabwe. As a result, esketamine is effectively unavailable as an on‑label, reimbursed treatment in Zimbabwe — access would require private importation with regulatory permission or use inside a formally approved clinical trial or compassionate‑use arrangement. # #

Ketamine hydrochloride is a legally approved anaesthetic and analgesic medicine in Zimbabwe and is procured for public hospitals (demonstrated by public procurement/tender listings), and it is therefore lawfully supplied and used in medical settings under normal regulatory controls for anaesthesia and other recognised indications. #

For psychiatric indications (low‑dose IV or subcutaneous ketamine for treatment‑resistant depression, PTSD, etc.), delivery in Zimbabwe currently occurs primarily through private clinics and hospital‑based specialist services operating on a referral basis; these services describe medically supervised infusion protocols and psychiatric oversight but are marketed and delivered as private (self‑pay) services rather than part of a national reimbursed mental‑health benefit. Examples of private ketamine therapy providers in Zimbabwe describe referral pathways, informed consent, and anaesthetic/psychiatric monitoring consistent with international off‑label practice. #

Regulatory context: ketamine remains a controlled medicine (its manufacture, importation, dispensing and use are subject to regulation), but established medical uses (notably anaesthesia) are supported by public hospital procurement and supply chains; off‑label psychiatric use is available privately and is not known to be covered by mainstream public health reimbursement or national insurance schemes. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Dangerous Drugs Act schedule explicitly lists DMT (N,N‑Dimethyltryptamine) among prohibited psychotropic substances. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The statutory schedules list a broad set of tryptamine derivatives (including DMT and related compounds) as prohibited; 5‑MeO‑DMT would fall under these controls and is not authorised for medical use outside approved research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine and similar indole alkaloids are not listed as authorised therapeutic agents in Zimbabwe and would be treated as prohibited unless specifically licensed for research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Components of ayahuasca such as DMT/other scheduled tryptamines are explicitly listed in the Dangerous Drugs Act; traditional plant brews containing scheduled compounds therefore fall within the statutory prohibitions unless used under a specific research or licensing exception. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline is explicitly named in the Dangerous Drugs Act schedule as a prohibited substance. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Dangerous Drugs Act schedule includes numerous phenethylamine/amphetamine analogues and related substances; 2C‑class compounds and similar designer phenethylamines are captured by the Act’s prohibitions and would only be lawful within a licensed research context. #